Illumina, Inc. (ILMN)
| Previous close | 414.08 |
| Open | 417.38 |
| Bid | 413.52 x 800 |
| Ask | 414.07 x 800 |
| Day's range | 412.51 - 417.98 |
| 52-week range | 288.01 - 555.77 |
| Volume | 107,297 |
| Avg. volume | 779,615 |
| Market cap | 64.811B |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | 79.30 |
| EPS (TTM) | 5.22 |
| Earnings date | 04 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 453.00 |
- Zacks
New Strong Sell Stocks for October 19th
ACCD, EAT, ILMN, MAXN, and TM have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2021
- Reuters
EU antitrust regulators resume Illumina, Grail probe, decision due by Feb. 4
EU antitrust regulators have resumed their scrutiny of U.S. life sciences company Illumina's bid for Grail Inc after a two-month temporary halt and will decide by Feb. 4 whether to clear the deal, a European Commission filing showed on Tuesday. The EU competition enforcer paused its investigation on Aug. 11 while waiting for Illumina to provide requested data. Last month it sent a statement of objections to Illumina for closing the deal before securing regulatory clearance, warning of interim measures.
- Motley Fool
Why Shares of Ilumina Slumped 11.3% in September
Shares of applied genomics company Ilumina (NASDAQ: ILMN) dropped 11.3% in September, according to data provided by S&P Global Market Intelligence. Ilumina's shares are still up more than 4% this year. The biggest thing hanging over Ilumina is its somewhat controversial purchase of liquid biopsy company Grail, which was once was a division of Ilumina but was spun off in 2016 into a separate company.
